Show simple item record

dc.contributor.authorMerriel, SWD
dc.contributor.authorHetherington, L
dc.contributor.authorSeggie, A
dc.contributor.authorCastle, JT
dc.contributor.authorCross, W
dc.contributor.authorRoobol, MJ
dc.contributor.authorGnanapragasam, V
dc.contributor.authorMoore, CM
dc.contributor.authorProstate Cancer UK Expert Reference Group on Active Surveillance
dc.date.accessioned2019-09-17T10:38:59Z
dc.date.issued2019-07
dc.identifier.citationBJU international, 2019, 124 (1), pp. 47 - 54
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3346
dc.identifier.eissn1464-410X
dc.identifier.doi10.1111/bju.14707
dc.description.abstractOBJECTIVES:To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS:A consensus statement was drafted on the basis of three sources of data: systematic literature search of national and international guidelines; data arising from a Freedom of Information Act request to UK urology departments regarding their current practice of AS; and survey and interview responses from men with localized prostate cancer regarding their experiences and views of AS. The Prostate Cancer UK Expert Reference Group (ERG) on AS was then convened to discuss and refine the statement. RESULTS:Guidelines and protocols for AS varied significantly in terms of risk stratification, criteria for offering AS, and protocols for AS between and within countries. Patients and healthcare professionals identified clinical, emotional and process needs for AS to be effective. Men with prostate cancer wanted more information and psychological support at the time of discussing AS with the treating team and in the first 2 years of AS, and a named healthcare professional to discuss any questions or concerns they had. The ERG agreed 30 consensus statements regarding best practice for AS. Statements were grouped under headings: 'Inclusion/Exclusion Criteria'; 'AS follow-up protocol' and 'When to stop AS'. CONCLUSION:Significant variation currently exists in the practice of AS in the UK and internationally. Men have clear views on the level of involvement in treatment decisions and support from their treating professionals when receiving AS. The Prostate Cancer UK AS ERG has developed a set of consensus statements for best practice in AS. Evidence for best practice in AS, and the use of multiparametric magnetic resonance imaging in AS, is still evolving, and further studies are needed to determine how to optimize AS outcomes.
dc.formatPrint-Electronic
dc.format.extent47 - 54
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectProstate Cancer UK Expert Reference Group on Active Surveillance
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectClinical Protocols
dc.subjectAttitude of Health Personnel
dc.subjectConsensus
dc.subjectMale
dc.subjectPractice Guidelines as Topic
dc.subjectPatient Preference
dc.subjectWatchful Waiting
dc.subjectPractice Patterns, Physicians'
dc.subjectUnited Kingdom
dc.titleBest practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bju.14707
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2019-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU international
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume124
pubs.embargo.termsNot known
dc.contributor.icrauthorParker, Chrisen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0